Premium
Differential Diagnosis of pancreatic ductal adenocarcinoma based on differential expression of select miRNA in pancreatic tissue and plasma
Author(s) -
Figueiredo Rafael Zimak,
Vieira Nivaldo Farias,
Cirino Mucio Luiz Assis,
Neto Fermino Sanches Lizarte,
Gaspar Alberto Facury,
Cunha Tirapelli Daniela Pretti,
Sankarankutty Ajith Kumar,
Kemp Rafael,
Santos José Sebastião
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2018.32.1_supplement.lb526
Subject(s) - medicine , pancreatic ductal adenocarcinoma , microrna , differential diagnosis , gastroenterology , pancreatic cancer , significant difference , adenocarcinoma , pathology , oncology , biology , cancer , gene , biochemistry
The differential diagnosis, treatment and prognosis of pancreatic ductal adenocarcinoma (PA) are still a challenge in clinical practice. The aim of the current study was to assess the role of select plasma and tissue microRNAs (miRs‐21, ‐23a, ‐100, ‐107, ‐181c e ‐210) as biomarkers for the diagnosis of PDCA. Samples of plasma (PAp Group, n=13), pancreatic tumors (PAt Group, n=18) and peritumoral regions (PPT Group, n=9) were collected from patients during the surgical procedure. The control group consisted of samples collected from patients submitted to pancreatic surgery for trauma or from cadaveric organ donors (PC Group, n=7). Healthy volunteers donated blood for plasma collection (PCp Group, n=6). The relative abundance of six miRNAs was measured in all groups using real‐time PCR, and serum CA 19‐9 levels were determined in Groups PA and PC, with the difference being considered significant when p <0.05. In tissue samples, there was a difference in the expression of miRNA‐21 (p=0.005) and miRNA‐210 (p=0.008) across the PAt, PC and PPT groups; miRNA‐21 distinguished group PAt from PC and PPT and miRNA‐210 distinguished group PAt from PC. Serum CA 19‐9 showed 88% accuracy (ROC‐AUC 0.95; 0.84 – 1), 83% sensitivity, and 100% specificity at a cut‐off of 37 ng/dl. The PAp group showed overexpression of miR‐181c (95% CI1.67 – 17.68; p<0.00001) and miR‐210 (95% CI0.16 – 5,20; p=0.03) compared to the PCp group. The combination of tissue expression of miR‐21, ‐210 and serum CA 19‐9 showed 100% accuracy for the diagnosis of PA, and the accuracy of plasma miR‐181c (PAp × PCp) was also 100%. These findings suggest that the combination of tissue miRNAs and serum CA 19‐9 can improve accuracy, but plasma miRNA expression can be used as a noninvasive diagnostic test for PA, although further studies are necessary to validate these results as well as to evaluate the utility of miRNA expression as a biomarker related to survival and to the response to therapy in PA. This abstract is from the Experimental Biology 2018 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .